SCHEMBL29944969

SCHEMBL29944969

O=C(Cl)Oc1ccccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
LMNA P02545 2/20 0.42
P4HTM Q9NXG6 2/20 0.42
NAPRT Q6XQN6 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KDM4E B2RXH2 3/20 0.41
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.41
CCR1 P32246 1/20 0.41
CCR5 P51681 1/20 0.41
CCR8 P51685 1/20 0.41
METAP1 P53582 1/20 0.41
BLM P54132 1/20 0.41
HIF1A Q16665 1/20 0.41
DOHH Q9BU89 1/20 0.41
ALDH1A1 P00352 2/20 0.41
TSHR P16473 1/20 0.40
NPC1 O15118 4/20 0.39
RAB9A P51151 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2523378 1.00 CES2 (0.43) CES2CES1LMNAP4HTMNAPRT
SCHEMBL450118 0.83 CES2 (0.46) CES2CES1LMNAP4HTMNAPRT
SCHEMBL11865903 0.83 CES2 (0.46) CES2CES1LMNAP4HTMNAPRT
SCHEMBL101751 0.81 LMNA (0.48) CES2CES1LMNAP4HTMNAPRT
SCHEMBL3676096 0.81 CES2 (0.45) CES2CES1LMNAP4HTMNAPRT
SCHEMBL28960343 0.81 CES2 (0.45) CES2CES1LMNAP4HTMNAPRT
SCHEMBL7351837 0.79 CES2 (0.43) CES2CES1LMNAP4HTMNAPRT
SCHEMBL7521569 0.79 CES2 (0.48) CES2CES1LMNAP4HTMNAPRT
SCHEMBL253858 0.79 CES2 (0.43) CES2CES1LMNAP4HTMNAPRT
SCHEMBL519065 0.79 CES2 (0.43) CES2CES1LMNAP4HTMNAPRT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4308552-A2 DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF Supernus Pharmaceuticals, Inc. (US) 2024-01-24 EP disclosed
WO-2022198062-A2 DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF SUPERNUS PHARMACEUTICALS, INC. (US) 2022-09-22 WO disclosed